Vascular normalization: a real benefit? (Q37884454)

24 August 2017

1 reference

title

Vascular normalization: a real benefit? (English)

1 reference

24 August 2017

Domenico Ribatti

1 reference

24 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21638121

3 December 2024

publication date

3 June 2011

1 reference

full work available at URL

24 August 2017

https://hal.archives-ouvertes.fr/hal-00703553/file/PEER_stage2_10.1007%252Fs00280-011-1683-z.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21638121

http://link.springer.com/content/pdf/10.1007/s00280-011-1683-z.pdf

3 December 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00280-011-1683-Z

http://link.springer.com/article/10.1007/s00280-011-1683-z/fulltext.html

3 December 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-011-1683-Z

http://link.springer.com/content/pdf/10.1007/s00280-011-1683-z

3 December 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-011-1683-Z

Cancer Chemotherapy and Pharmacology

3 December 2024

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

275-278

1 reference

Tumor angiogenesis: therapeutic implications

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

The structure of the vascular network of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Imaging of angiogenesis: from microscope to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

The history of the angiogenic switch concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Antiangiogenic therapies for high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Encountering and advancing through antiangiogenesis therapy for gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1683-Z

21 January 2018

Advances in chemotherapy

EK Marchall Jr

1964

1 reference

https://api.crossref.org/works/10.1007/S00280-011-1683-Z

3 December 2024

Invasion & Metastasis

385

DR Senger

1995

1 reference

https://api.crossref.org/works/10.1007/S00280-011-1683-Z

Tumor induction of VEGF promoter activity in stromal cells

3 December 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-011-1683-Z

Persistent vascular normalization as an alternative goal of anti‐angiogenic cancer therapy

3 December 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-011-1683-Z

The role of pericytes in angiogenesis

3 December 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-011-1683-Z

3 December 2024

Identifiers

1 reference

24 August 2017

1 reference